[go: up one dir, main page]

Cholerton et al., 1992 - Google Patents

The role of individual human cytochrpmes P450 in drug metabolism and clinical response

Cholerton et al., 1992

Document ID
6900072929506995852
Author
Cholerton S
Daly A
Idle J
Publication year
Publication venue
Trends in pharmacological sciences

External Links

Snippet

Recent advances in the study of human cytochromes P450 by protein purification, molecular cloning techniques and analysis of polymorphisms has led to increased understanding of the role of the various forms in the metabolism of clinically important drugs. In particular, the …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Similar Documents

Publication Publication Date Title
Cholerton et al. The role of individual human cytochrpmes P450 in drug metabolism and clinical response
Bjornsson et al. A review and assessment of potential sources of ethnic differences in drug responsiveness
Kirchheiner et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics
Hamelin et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
Scordo et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population
Kumar et al. Role of drug metabolism in drug discovery and development
Foster et al. Methadone N‐demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4
Vandel et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
Jeppesen et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
Brøsen et al. Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Sauer et al. Clinical pharmacokinetics of atomoxetine
JP3704290B2 (en) Use of CYP2D6 inhibitors in combination therapy
Meyer et al. Molecular mechanisms of genetic polymorphisms of drug metabolism
Dahl Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Ketter et al. The emerging role of cytochrome P450 3A in psychopharmacology
Shah Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing
Masimirembwa et al. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants
Pollock Recent developments in drug metabolism of relevance to psychiatrists
Scordo et al. Cytochrome P450 polymorphisms and response to antipsychotic therapy
Lefebvre et al. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension
Donahue et al. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19
Sharma et al. A convenient five‐drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study
Coutts Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping
Xu et al. Phenotypic polymorphism of CYP2A6 activity in a Chinese population
Puozzo et al. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants